Loading
Life sciences · Journal article
npj Breast Cancer · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
PARP inhibitors have transformed treatment of BRCA1/2 -mutated breast cancer but remain limited by acquired resistance, restricted activity in homologous recombination–proficient tumors, and PARP2-related toxicity. This review examines two advances redefining the class: next-generation PARP1-selective inhibitors with improved therapeutic indices, and rational combinations with DNA-repair, epigenetic, immune, endocrine, and antibody-drug conjugate partners. Together, these strategies mark a shift from monotherapy toward mechanism-based combinations that broaden benefit across breast cancer subtypes.